NCT07073053View on ClinicalTrials.gov

The Role of Glucagon-Like Peptide-1 Receptor Agonists in Coronary Artery Diseases and Their Potential Mechanisms

PHASE4Not yet recruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

October 1, 2025

Primary Completion Date

July 31, 2028

Study Completion Date

July 31, 2028

Conditions
Glucagon-Like Peptide-1 Receptor AgonistsType 2 DiabetesCoronary Arterial Disease (CAD)
Interventions
DRUG

Semaglutide 1.0 mg

add-on current standard treatment which includes SGLT2 inhibitor

DRUG

Semaglutide 0.5 mg

add-on current standard treatment which includes SGLT2 inhibitor

Trial Locations (1)

112

Taipei Veterans General Hospital, Taipei

All Listed Sponsors
lead

Taipei Veterans General Hospital, Taiwan

OTHER_GOV